📰 Bcli News
Page 3 - Bcli News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bcli. Real-time updates on events, politics, business and more.
May 30, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,870,000 shares, a decline of 9.2% from the April 30th total of 3,160,000 shares. Approximately 9.5% of the company’s stock are short sold. […]
May 13, 2023
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday. Separately, Maxim Group increased their target price on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, […]
May 13, 2023
StockNews.com downgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a report issued on Friday morning. Separately, Maxim Group boosted their price target on Brainstorm Cell Therapeutics from $5.00 to $10.00 and gave the company a buy rating in a report on Friday, March 31st. […]
May 4, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) saw a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,930,000 shares, a decrease of 5.5% from the March 31st total of 3,100,000 shares. Currently, 10.4% of the company’s stock are sold short. Based on an […]
April 28, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.20 and traded as high as $3.16. Brainstorm Cell Therapeutics shares last traded at $2.78, with a volume of 440,422 shares trading […]
April 20, 2023
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Rating) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,100,000 shares, a growth of 29.7% from the March 15th total of 2,390,000 shares. Currently, 11.0% of the company’s stock are sold short. Based on an […]
April 2, 2023
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, Yahoo Finance reports. During the same quarter in the prior year, the company earned ($0.17) EPS. Brainstorm Cell Therapeutics Stock Performance BCLI traded up […]
March 31, 2023
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) released its earnings results on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04, Yahoo Finance reports. During the same period in the prior year, the firm posted ($0.17) earnings per share. Brainstorm Cell Therapeutics Trading Up 32.0 % […]
March 30, 2023
StockNews.com cut shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note released on Sunday morning. Brainstorm Cell Therapeutics Price Performance BCLI opened at $2.44 on Friday. Brainstorm Cell Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $4.70. […]
March 29, 2023
StockNews.com lowered shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Sunday morning. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ BCLI opened at $1.84 on Friday. The firm has a market cap of $67.23 million, a price-to-earnings ratio […]